Biotechs Aim for Public Markets with Less Cash in their Coffers
This article was originally published in Start Up
An analysis of the total private money raised by US biotechs that have managed to squeeze through the public financing window since it reopened in 2003 shows that in general, better funded private companies have had an edge over less well funded firms when making it to the public markets-they hit the public financing window first and their VC investors have had to put up with less dilution.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.